FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
by Amber Baker and Barbara Loe Fisher
The U.S. Food and Drug Administration (FDA) has licensed Sanofi’ SA’s four-valent MenQuadfi meningococcal vaccine for use in infants aged six weeks ...
‘All New Vaccines’ in the U.S. to Undergo Placebo-Controlled Safety Testing
by Barbara Loe Fisher and Amber Baker
On Apr. 30, 2025, the U.S. Department of Health and Human Services (DHHS) announced that all newly developed vaccines will ...
HHS Halts Funding for Development of Next-Generation COVID Biologics
by Amber Baker
The U.S. Department of Health and Human Services (DHHS) has stopped U.S. government funding for the development of next-generation COVID-19 ...
Fast-Tracked DNA-Based Therapeutic Cancer Vaccine to Be Given to Melanoma Patients in U.K.
by Natasha Hobley
Patients in England with advanced skin melanoma are receiving a “revolutionary” new therapeutic cancer vaccine in a National Health Service ...
Gates Foundation Awards $8.6 Million to Expand Development of Multi-Dose Pediatric Vaccines Using Novel Adjuvants
by TVR Staff
On Dec. 5, 2024, formulation technology company VitriVax, Inc. of Boulder, Colorado was awarded a two-year, $3.6 million grant by ...
WHO Names 17 Pathogens as Top Priorities for Global Vaccine Development
by Amber Baker
A new World Health Organization (WHO) study published in eBioMedicine last week highlights 17 viral and bacterial pathogens that are ...
Moderna/Merck’s Combo Melanoma Cancer mRNA Therapeutic May Be Ready Next Year
by TVR Staff
The CEO of Moderna, Inc., Stephane Bancel, said last week that his company may introduce a new mRNA (messenger ribonucleic ...
U.S. Government Gives Moderna $176 Million to Develop mRNA Bird Flu Biologic
by Amber Baker
On July 2, 2024, the U.S. government awarded a $176 million contract to Moderna, Inc. for the development of an ...
BARDA Awards $9.27 Million Contract to Evaluate Oral Pill COVID Vaccine
by TVR Staff
Biotechnology firm Vaxart, Inc. announced on Jan. 19, 2024 that it received a $9.27 million contract from the U.S. Biomedical ...
In this section
Latest
Popular
Comments
Latest
FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
by Amber Baker and Barbara Loe Fisher
Popular
Comments
Allie on FDA Licenses Moderna’s mNEXSPIKE COVID Shot for Individuals at High Risk for Severe COVID Disease
CAWS on Oral Rabies Vaccine Deployed by Air to Vaccinate Wildlife in Vermont
Nicki Cooke on FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
B.C. on FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
CATRYNA WHITE on FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
